Verve Therapeutics Inc (NASDAQ: VERV) closed the day trading at $7.60 down -5.82% from the previous closing price of $8.07. On the day, 1185455 shares were traded.
Ratios:
For a better understanding of VERV, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.24 and its Current Ratio is at 17.24. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 08, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $29.
On February 01, 2023, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $21.Cantor Fitzgerald initiated its Neutral rating on February 01, 2023, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when Nickerson Joan sold 1,514 shares for $8.24 per share. The transaction valued at 12,475 led to the insider holds 8,659 shares of the business.
Dorval Allison sold 554 shares of VERV for $6,343 on Nov 29 ’23. The Chief Financial Officer now owns 4,060 shares after completing the transaction at $11.45 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 50.76 while its Price-to-Book (P/B) ratio in mrq is 1.04.
Stock Price History:
Over the past 52 weeks, VERV has reached a high of $21.42, while it has fallen to a 52-week low of $7.36.
Shares Statistics:
A total of 81.97M shares are outstanding, with a floating share count of 54.79M. Insiders hold about 30.25% of the company’s shares, while institutions hold 70.27% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from VERS analysts. The consensus estimate for the next quarter is $1.52, with high estimates of $7.60 and low estimates of $0.18.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
